$0.76
-0.02 (-2.42%)
Open$0.78
Previous Close$0.78
Day High$0.78
Day Low$0.74
52W High$1.69
52W Low$0.55
Volume—
Avg Volume144.6K
Market Cap9.38M
P/E Ratio—
EPS$-1.08
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+4,639.7% upside
Current
$0.76
$0.76
Target
$36.06
$36.06
$23.45
$36.06 avg
$38.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 545.5K | 1.10M | 1.13M |
| Net Income | -24,052,037 | 89.2K | 117.7K |
| Profit Margin | -4,409.1% | 8.1% | 10.4% |
| EBITDA | -25,221,623 | 177.4K | 182.1K |
| Free Cash Flow | — | 70.9K | 72.7K |
| Rev Growth | — | +5.3% | -7.0% |
| Debt/Equity | — | 0.17 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |